MannKind Corporation says that it will move ahead with a Phase 1 SAD/MAD study of MNKD-201 dry powder nintedanib for inhalation, which the company is developing for the treatment of fibrotic diseases of the lung, including idiopathic pulmonary fibrosis (IPF). The trial is expected to begin enrolling healthy volunteers in June 2024.
MannKind CEO Michael Castagna commented, “We are pleased to progress nintedanib DPI which comes on the heels of furthering our Phase 3 study of Clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung diseases. This puts two studies in motion by mid-year that will explore potential treatment options for patients living with serious lung diseases.”
Read the MannKind press release.
